- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Interventions
- Trastuzumab deruxtecan, Lovastatin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
- Interventions
- Patritumab deruxtecan, Trastuzumab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more
- Conditions
- Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer, Breast Cancer, Breast Cancer Female
- Interventions
- Elacestrant, Trastuzumab Deruxtecan
- Drug
- Lead sponsor
- Kristina A. Fanucci
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2038
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts